FDA
-
-
-
-
-
-
-
Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update
-
-
-
-
-
-
-
Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens
-
-
-
-
-
-
-
Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL® (Benzgalantamine) for Alzheimer’s Disease
-
-
-
-
-
-
-
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens
-
-
-
-
-
-
-
Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYLTM for Mild to Moderate Alzheimer’s Disease
-
-
-
-
-
-
-
Alpha Cognition to Present at the Life Science Investor Forum March 7th
-
-
-
-
-
-
-
Alpha Cognition Announces First Quarter 2023 Results and Provides Corporate Update
-
325,324 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

